NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/08/2026
Voltar para busca
Dado oficial do USPTO
XCUBE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
XCUBE
ST13
US500000079320193Classe
9, 35, 42, 44
Pedido
79320193
Registro
8200099
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
56
Atualização mais recente
06/08/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
9, 35, 42, 44
Data de depósito
25/02/2021
Data de registro
07/04/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/04/2026
Última transação
06/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
DE
Examinador
IN, SUNG HYUN
Unidade examinadora
L30
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Immatics Biotechnologies GmbH
Representantes
Anna Kurian Shaw Hogan Lovells US LLP
Classificação técnica
Classes Nice
Classe 9Classe 35Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 9
Recorded bioinformatics software for data processingdata engineeringdata sciencepredictive modeling and statistical modeling and machine learning in the field of immunotherapies; recorded graphical user interface software for data processingdata engineeringdata sciencepredictive modeling and statistical modeling and machine learning in the field of immunotherapies; recorded artificial intelligence and machine learning software for genome analysisdeveloping personal treatment strategies for patients with diagnosed canceranalyzingscreeningidentifyingquantifyinginterpreting data in the field of mass spectrometry and next-generation sequencing (NGS); electronic databases for bioinformatic purposes; next-generation sequencing (NGS) data processor; bioinformatics data processor; none of the foregoing in connection with HVAC systems or components thereof
Classe 35
Compilation of statistical data and models with respect to cancer treatment and cancer diagnosis
Classe 42
Computer programming in the medicalpharmaceutical and biotechnological field; database design in the medicalpharmaceutical and biotechnological field; maintenance of database software in the medicalpharmaceuticalbiotechnological field; programming of software for importing and managing data in the medicalpharmaceuticalbiotechnological field; information technology IT consulting services for the pharmaceutical and healthcare industries relating to data processingdata engineeringdata sciencepredictive modeling and statistical modeling and machine learning in the field of immunotherapies; computer programming for data processing; conducting evaluations in the field of pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development and evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer; technical research in the field of pharmaceutical studies; development of platform technologycancer immunotherapy platforms for manufacturing therapeutics; conducting clinical trials in the field of pharmaceuticals for the treatment and prevention of cancer; providing scientific molecular and genomic information for medical and clinical researchfor the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; research and development of medicines and diagnostic agents for cancer treatment and cancer diagnosis; providing scientific advice in the fields of cancer biologycancer treatmentpharmaceutical side effectsgenomicscancer medicine and translational medicine; providing scientific analysis in the field of next-generation sequencing (NGS) with respect to the analysis and interpretation of genomic data obtained from cancer patients; providing an onlinenon-downloadable computer software platform for purposes of storing and providing information about an individual's cancer profile and genomic changes to enable physicians and healthcare professionals to optimize treatment in clinical practice; research and development services in the field of immunology; none of the foregoing in connection with HVAC systems or components thereof
Classe 44
Medical and pharmaceutical consultancy services
Publicações
Histórico de despachos e eventos da marca no USPTO.
56 publicações encontradas
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/07/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/04/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
07/04/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/02/2026
PUBO
PUBLISHED FOR OPPOSITION
17/02/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/02/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
23/01/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/01/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/01/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/01/2026
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/07/2025
GNRT
NON-FINAL ACTION E-MAILED
08/07/2025
CNRT
NON-FINAL ACTION WRITTEN
08/07/2025
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
16/05/2025
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
15/11/2024
GNSL
LETTER OF SUSPENSION E-MAILED
15/11/2024
CNSL
SUSPENSION LETTER WRITTEN
15/11/2024
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
20/04/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
29/03/2024
DOCK
ASSIGNED TO EXAMINER
29/03/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
25/03/2024
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
25/09/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
14/03/2023
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
27/02/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
22/02/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
22/02/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/01/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/01/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
30/01/2023
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
28/11/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/11/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/11/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/11/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/11/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/11/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/10/2022
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
13/05/2022
GNSL
LETTER OF SUSPENSION E-MAILED
13/05/2022
CNSL
SUSPENSION LETTER WRITTEN
13/05/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/05/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/05/2022
ALIE
ASSIGNED TO LIE
10/05/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
06/05/2022
RFNT
REFUSAL PROCESSED BY IB
29/11/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/11/2021
RFRR
REFUSAL PROCESSED BY MPU
08/11/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
14/10/2021
CNSL
SUSPENSION LETTER WRITTEN
13/10/2021
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
07/10/2021
MAFR
APPLICATION FILING RECEIPT MAILED
24/09/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
22/09/2021
CNSL
SUSPENSION LETTER WRITTEN
21/09/2021
DOCK
ASSIGNED TO EXAMINER
21/09/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/09/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
16/09/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace XCUBE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.